BIOCON · NSE
Biocon Limited
₹385
+1.32% (+₹5)
Prev. close
₹380
Volume
79,01,211
Delivery %
80.1%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Biocon, recommending a buy at CMP ₹426.8 with a target of ₹470 and a stop-loss at ₹405. The stock has confirm…” | Ajit MishraReligare Broking | Biocon | NOT GRADED |
Fundamentals
About Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shreehas Pradeep Tambe MTech
Headquarters
Bengaluru
Employees
16,447
Website
biocon.comExchange
View on NSE ↗Key stats
Market cap
₹61,875.17 Cr
P/E ratio (TTM)
108.6
Dividend yield
0.13%
EPS (TTM)
₹3.50
Beta (1Y · daily vs NIFTY 50)
0.67
Beta (5Y · monthly vs NIFTY 50)
0.94
Shares float
80.18 Cr
EPS · quarter ended Jun 2026
₹0.87
Upcoming earnings
11 Nov 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 2.2% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹7,105.80 Cr | ₹8,184.00 Cr | ₹11,174.20 Cr | ₹14,755.70 Cr | ₹15,261.70 Cr | ₹16,927.00 Cr | |
| EBITDA | ₹1,919.70 Cr | ₹2,071.80 Cr | ₹2,429.20 Cr | ₹4,068.40 Cr | ₹4,471.00 Cr | ₹3,394.90 Cr |
| ₹740.50 Cr | ₹648.40 Cr | ₹462.70 Cr | ₹1,022.50 Cr | ₹1,013.30 Cr | ₹385.60 Cr | |
| Diluted EPS | ₹6.19 | ₹5.42 | ₹3.87 | ₹8.54 | ₹8.46 | ₹2.82 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹18,490.00 Cr | ₹20,342.00 Cr | ₹51,742.00 Cr | ₹55,753.00 Cr | ₹58,540.00 Cr | ₹63,409.00 Cr | |
| ₹4,481.10 Cr | ₹5,146.60 Cr | ₹18,018.80 Cr | ₹16,276.70 Cr | ₹18,362.00 Cr | ₹15,434.10 Cr | |
| Stockholders' equity | ₹7,627.00 Cr | ₹8,432.00 Cr | ₹17,867.00 Cr | ₹19,783.00 Cr | ₹21,644.00 Cr | ₹34,031.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,160.00 Cr | ₹1,177.00 Cr | ₹1,852.00 Cr | ₹2,954.00 Cr | ₹4,061.00 Cr | ₹1,994.00 Cr | |
| Investing cash flow | ₹-3,624.70 Cr | ₹-1,699.10 Cr | ₹-14,281.80 Cr | ₹-1,004.50 Cr | ₹-234.10 Cr | ₹-2,082.10 Cr |
| ₹2,564.00 Cr | ₹242.00 Cr | ₹13,049.00 Cr | ₹-2,333.00 Cr | ₹-1,854.00 Cr | ₹-924.00 Cr | |
| Capital expenditure | ₹-1,746.30 Cr | ₹-6,226.80 Cr | ₹-1,726.30 Cr | ₹-1,931.60 Cr | ₹-2,343.30 Cr | ₹-1,911.70 Cr |
| End cash position | — | ₹653.70 Cr | ₹1,294.80 Cr | ₹919.50 Cr | ₹2,923.80 Cr | ₹2,111.50 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25–Jun 25(2Q) | Sep 25 | Dec 25 | Jan 26 | Jan 26 | Mar 26 | Jun 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 60.64% | 54.45% | 54.45% | 54.45% | 48.27% | 44.91% | 44.91% | 44.68% |
| Public | 38.64% | 38.71% | 38.74% | 38.63% | 38.74% | 38.78% | 38.81% | 38.87% | 38.97% | 39.03% | 39.05% | 39.08% | 39.12% | 39.14% | 39.15% | 45.37% | 45.41% | 45.43% | 51.63% | 54.99% | 55.00% | 55.27% |
| Employee trusts | 0.72% | 0.65% | 0.63% | 0.73% | 0.63% | 0.58% | 0.55% | 0.49% | 0.39% | 0.33% | 0.32% | 0.28% | 0.25% | 0.22% | 0.21% | 0.18% | 0.14% | 0.12% | 0.10% | 0.10% | 0.09% | 0.05% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Biocon Limited | ₹60,963.32 Cr | ₹380 | 111.1 | 1.79 | 1.1% | 0.45 | +11.5% | +7.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 24
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
33 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Biocon Stock Gains As Rs 635 Cr Block Deal Changes 1% Stake; Biosimilars Growth In Focus
Biocon shares rose after a block deal saw 1% of its equity, or 1.65 crore shares, change hands for Rs 635 crore. This transaction, possibly marking an investor's exit, occurred as the company focuses on growing its biosimilars business. Biocon aims for $1 billion in biosimilars revenue, driven by strong insulin demand and new products.